Human papillomavirus-specific immune therapy: failure and hope

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Prophylactic vaccines targeting oncogenic human papillomaviruses (HPV; serotypes 16 and 18) are available.
• These vaccines effectively prevent persistent HPV infection and precancerous lesions.

Purpose of the Study:

• To evaluate the impact of prophylactic HPV vaccines on the natural history of prevalent HPV infections.
• To identify the need for immune therapeutic strategies for individuals with persistent HPV infections.
• To analyze the reasons for the failure of previous HPV-specific therapies and explore future developments.

Main Methods:

• Review of clinical trial data for prophylactic HPV vaccines.
• Analysis of existing HPV-specific therapeutic approaches.
• Discussion of promising developments and future directions in HPV therapy.

Main Results:

• Prophylactic HPV vaccines do not influence the natural history of prevalent HPV infections or their progression to cancer.
• Significant cancer incidence reduction from prophylactic vaccines is expected only after two decades.
• There is a clear need for therapeutic strategies for individuals with persistent HPV infections.

Conclusions:

• Current prophylactic HPV vaccines do not offer therapeutic benefits for existing infections.
• Future research should focus on developing effective HPV-specific immune therapies.
• Addressing persistent HPV infections is crucial for reducing cancer burden in the short to medium term.